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The extracellular matrix (ECM) is a complex network of secreted proteins which provides
support for tissues and organs. Additionally, the ECM controls a plethora of cell
functions, including cell polarity, migration, proliferation, and oncogenic transformation.
One of the hallmarks of cancer is altered cell metabolism, which is currently being
exploited to develop anti-cancer therapies. Several pieces of evidence indicate that the
tumor microenvironment and the ECM impinge on tumor cell metabolism. Therefore,
it is essential to understand the contribution of the complex 3D microenvironment
in controlling metabolic plasticity and responsiveness to therapies targeting cell
metabolism. In this mini-review, we will describe how the tumor microenvironment
and cancer-associated fibroblasts dictate cancer cell metabolism, resulting in increased
tumor progression. Moreover, we will define the cross-talk between nutrient signaling and
the trafficking of the ECM receptors of the integrin family. Finally, we will present recent
data highlighting the contribution of nutrient scavenging from the microenvironment to
support cancer cells growth under nutrient starvation conditions.
Keywords: extracellular matrix, cell metabolism, cancer associated fibroblasts, nutrient scavenging, nutrient
signaling
INTRODUCTION
Cancer-associated fibroblasts (CAFs) are a heterogenous and plastic population of activated
fibroblasts, which represent a significant proportion of the tumor microenvironment. For instance,
CAFs can account up to 70 and 90% of breast and pancreatic cancer tumor mass, respectively (1, 2).
The role of CAFs in tumorigenesis is widely established and they have been shown to contribute
to tumor growth, metastasis and resistance to therapy (3). Moreover, CAFs play an important role
in the regulation of cancer metabolism, primarily through the secretion of metabolites and the
generation of a stiffer and fibrotic ECM, which in turn affects cancer cell metabolism.
Cells interact with the ECM through plasma membrane receptors. Integrins are transmembrane
receptors that regulate cell adhesion, migration, and mechanotransduction through mediating cell-
ECM interaction (4, 5). Integrins can trigger different intracellular signaling pathways promoting
cell growth, survival, and proliferation (6). Furthermore, ligand bound-integrin trafficking has
recently been shown to directly or indirectly affect nutrient signaling (7, 8). Mechanistic target of
Rapamycin (mTOR) signaling pathway is the key regulator of anabolic and catabolic processes of
the cells. During nutrient availability, mTOR induces anabolic processes such as protein, nucleotide,
and lipid biosynthesis and inhibits cellular autophagy and lysosomal biogenesis (9–11). mTOR
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forms two independent complexes, mTORC1 and mTORC2.
mTORC1 adjusts cell growth and proliferation in response to
growth factors and amino acids, while mTORC2 has a role
in actin organization. Furthermore, mTORC2 can control cell
proliferation and survival through AKT activation downstream
of growth factor signaling (12). During nutrient starvation, the
activity of mTORC1 is restrained, allowing the cells use other
sources of nutrient acquisition, such as autophagy (13).
In cancer cells, the activation of oncogenic signaling has a
profound effect on cell metabolism. Indeed, aberrant activation
of phosphatidyl inositol 3 kinase (PI3K)/AKT and Ras signaling
pathways facilitates constant glucose uptake through GLUT1
receptor (14, 15). In parallel, derailed function of the oncogenic
protein c-myc induces the expression of glutamine transporters
and glutamine-utilizing enzymes (16, 17). In addition, high rate
of tumor growth and insufficient vasculature forming deep inside
the tumors significantly increase the chance of nutrient scarcity in
the tumor microenvironment (TME) (18). Indeed, the TME has
been shown to be depleted of amino acids and glucose (19, 20).
In this mini-review, we will highlight how CAFs control
cancer cell metabolism, through metabolite secretion and
the generation of a stiffer microenvironment. We will
then summarize the cross-talk between integrin trafficking,
metabolism and nutrient signaling and we will describe the
different mechanisms through which cancer cells can exploit
unconventional nutrient sources.
THE TUMOR MICROENVIRONMENT AND
CAFs DICTATE CHANGES IN CANCER
CELL METABOLISM
The activation of fibroblasts to CAFs is coupled with a metabolic
shift to glycolysis, increased catabolic activity and autophagy (21).
As a result of this, CAFs secrete a variety of metabolites that can
support cancer cell growth and metabolism.
In prostate cancer, CAFs promote the so-called
reverse Warburg effect, whereby lactate secretion and
mitochondria transfer from CAFs to cancer cells (CCs)
lead to an increase in mitochondrial activity and oxidative
phosphorylation (OXPHOS) in CCs (Figure 1A). This
promotes epithelial-to-mesenchymal transition, metastatic
burden, and chemotherapy resistance (22). Similarly,
the secretion of pyruvate by CAFs has been shown to
promote lymphoma cell survival through the upregulation
of the tricarboxylic acid (TCA) cycle (23) (Figure 1B), as
well as ECM remodeling and lung metastasis in breast
cancer, through the upregulation of alpha ketoglutarate
production (24).
In ovarian cancer, CAFs have been shown to promote
glycogen metabolism and glycolysis in CCs, through the
production of cytokines, which is in turn promoted by CC-
derived TGFβ. This CAFs-CC signaling loop results in increase
CC proliferation, invasion and metastasis (25) (Figure 1C).
It is important to note that all the afore-mentioned studies
were performed using conditioned media from CAFs or short-
term co-culture experiments (a few hours). Despite providing
useful insight in the contribution of secreted factors, these
fail to recapitulate the complex 3D structure of the TME,
whereby changes in ECM composition and properties could
play a role in the metabolic reprogramming observed in these
studies. Indeed, the stiffness of the TME has been shown to
have profound effects on both CAF and CC metabolism in
squamous cell carcinoma, leading to an increase in glycolysis and
glutamine consumption in both cell populations. In particular,
the activation of the YAP/TAZ signaling pathway in stiffer
environments promotes the expression of glycolytic enzymes
(26), as well as glutamine uptake and conversion to glutamate
in CCs. Glutamate is secreted by CCs and utilized by CAFs
for maintaining redox homeostasis through the glutathione
pathway. CAFs, on the other hand, secrete aspartate, which is
used by CCs to promote nucleotide synthesis (27) (Figure 1D).
Similar results have been observed in vivo in an orthotopic
mouse model of breast cancer, where ECM stiffness is coupled
with increased glycolysis, glutamine metabolism and aspartate
production. Importantly, a reduction in intratumoral levels of
aspartate and glutamine leads to a decrease in cell proliferation
(27). Interestingly, glutamate secretion by CCs is also involved in
the invasive phenotype of breast cancer cells. Indeed, by binding
to its receptor GRM3, glutamate promotes the trafficking of
the matrix metalloprotease MT1-MMP, leading to CC invasive
migration (28).
CAFs have a pivotal role in determining the composition
and organization of the ECM within the TME, although other
cell types have been shown to contribute to ECM secretion
and deposition. Increased collagen density is observed during
carcinoma progression and has been shown to be mainly
produced by CAFs (29). Importantly, changes in collagen
density have been linked with alterations in breast cancer cell
metabolism. High density collagen gels are associated with a
reduction of oxygen consumption and the amount of glucose
that is metabolized through the TCA cycle, with a concomitant
increase in the use of glutamine to fuel the TCA cycle. This
is associated with a reduction in the expression of glycolysis
genes and an increase in oxidative glutamine metabolism, serine
synthesis and one carbon metabolism enzymes (30) (Figure 1E).
This is in contrast with the data presented above by Bertero
et al. (27). This could be due to differences in the type
of cells analyzed (ovarian cancer vs. breast cancer), or the
experimental settings (hydrogels with different stiffnesses vs.
collagen I gels with different densities). Moreover, independent
sets of metabolic enzymes where shown to be modulated in
the two studies, suggesting that separate mechanotransduction
pathways could impinge on cell metabolism. Within the TME,
the ECM is constantly remodeled through the action of matrix
degrading enzymes. Recent data indicate that the degradation
of hyaluronan, a ubiquitous ECM component, promotes glucose
uptake in several cancer cell lines, by increasing the plasma
membrane localization of the glucose transporter GLUT1. This in
turns fosters glycolysis and promotes cancer cell migration (31).
It is unclear whether the degradation of other ECM components
is also linked to changes in cell metabolism. Moreover, future
work will be needed to characterize how ECM degradation in
more complex 3D environments impinges on CC metabolism.
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FIGURE 1 | Schematic representation of different mechanisms through which cancer-associated fibroblasts (CAFs) can modify cancer cell (CC) metabolism.
OXPHOS, oxidative phosphorylation; TCA, tricarboxylic acid cycle; Glu, glutamate; Asp, aspartate; ECM, extracellular matrix. (A) Lactate secreted by CAFs promotes
OXPHOS in pancreatic CCs. (B) CAF-derived pyruvate promotes TCA activation in lymphoma CCs. (C) Cytokines and TGF beta promote CAF-ovarian CC cross-talk.
(D) Asp secreted by CAFs drives nucleotide synthesis in squamous cell carcinoma. (E) ECM density promotes Serine synthesis and Gln metabolism in breast cancer.
THE CROSSTALK BETWEEN CELL
METABOLISM AND THE TRAFFICKING
AND FUNCTION OF THE ECM
RECEPTORS OF THE INTEGRIN FAMILY
mTOR is one of the signaling pathways that has been shown to
be regulated by integrin trafficking. It has been demonstrated
that in ovarian cancer cells, glucose starvation induces the
translocation of α5β1 integrin from peripheral focal adhesions
to a centrally located patch of fibrillar adhesions. This has been
identified as the main internalization site for fibronectin (FN)-
bound α5β1, resulting in tensin and Arf4-dependent endocytosis
and lysosomal delivery of FN-bound α5β1. This internalization
pathway leads to mTORC1 lysosomal recruitment and activation
(Figure 2A). Mimicking nutrient depleted environments by
inhibiting mTORC1 activity leads to higher ligand-bound α5β1
integrin endocytosis and tensin-dependent sub-nuclear adhesion
formation, showing that tensin-dependent α5β1 internalization
is controlled by nutrient availability (7). Serum and growth
factor starvation also induce normal mammary epithelial cells
to internalize soluble laminin through β4 integrin; this mediates
an increase in the cellular amino acid content through laminin
lysosomal degradation and amino acid extraction, which in turn
returns mTORC1 activity to its normal condition to avoid excess
uptake of extracellular proteins (Figure 2A). In vivo studies
also reveal that mammary epithelial cells in dietary restricted
mice increase laminin uptake from the basement membrane and
fibroblast ECM secretion (8). Altogether, these data indicate that
the uptake of ECM components, regulated by integrin trafficking
under nutrient deficient conditions, could provide a source of
nutrients for cancer cells. However, more studies are required to
investigate whether different integrin heterodimers are involved
in the internalization of other ECM components andwhether this
is required for nutrient signaling as well.
AMP-activated protein kinase (AMPK) is a serine/threonine
kinase that also works as a sensor for the availability of nutrients.
Lack of energy and cell exposure to certain levels of stress activate
AMPK, which inhibits anabolic pathways and induces catabolic
pathways to provide more energy or source of nutrition for
the cells (32). It has been revealed that AMPK can inhibit the
activation of α5β1 integrins in fibroblasts. In particular, AMPK
reduces tensin3 expression, thus preventing integrin activation
(Figure 2A). In AMPKKOmouse embryonic fibroblasts (MEFs),
the activity of α5β1 is increased, leading tomore fibrillar adhesion
formation and fibronectin biogenesis (33). More evidence is
required to evaluate the effect of higher fibronectin biogenesis
on nutrient signaling/availability for cells, since previous studies
highlighted that active integrins in fibrillar adhesion would
lead to higher fibronectin endocytosis under starvation (7). In
addition, since cancer cells are more prone to face nutrient
scarcity, more investigations are required to elucidate the effect of
AMPK activity in those cells. Even though studies on mTORC1
activity suggest that nutrient deficiency assist cells to benefit
from alternative food sources such as fibronectin and laminin
through receptor dependent (integrin)-endocytosis, this study
shows that starvation could also have an inhibitory effect on
integrin membrane transport and trafficking. As it has been
reviewed by Georgiadou and Ivaska (34), AMPK activity in
cancer cells and cancer associated fibroblast cells (CAFs) lead to a
cross-talk between them. Low activity of AMPK in CAFs induces
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FIGURE 2 | (A) Schematic representation of the crosstalk between integrins trafficking and cell metabolism. Nutrient starvation induces ligand (fibronectin or
Laminin)-bound integrin internalization through mTORC1 deactivation. On the other hand, activation of AMPK during starvation inhibits tensin expression, opposing
integrin activation. There is also a link between integrin mechanosensing and sphingolipid production through CD98hc protein, which is an integrin co-receptor
sensing mechanical forces. Activation of CD98hc induces sphingolipid production leading to activation of Src and GEF-H1 upstream of RhoA. (B) Schematic
representation of the molecular mechanisms through which nutrient starvation controls macropinocytosis. Macromolecules internalization under nutrient starvation is
induced through Ras and growth factor dependent mechanisms. Amino acids extracted from protein uptake can be used to feed the TCA cycle to make ATP or they
may be used to make other proteins.
tensin expression leading to upregulation of ECM secretion and
formation of fibrillar adhesion. In contrast, high AMPK activity
in cancer cells under starvation inhibits mTORC1 activity which
results in ECM internalization and lysosomal degradation to
provide nutrient for the cells.
In addition to signaling pathways that directly deal with
nutrient availability around the cells, a link between integrin
mechanosensing and cell metabolism has also been proposed.
CD98hc is an integrin co-receptor and amino acid transporter
sensing mechanical forces and causing cell stiffening through
integrin and RhoA activation. It has been demonstrated that
there is a cross-talk between mechanosensing interruption and
sphingolipid synthesis in fibroblasts bearing C330S mutation in
CD98hc. Sphingolipids are essential membrane components that
can regulate transmembrane protein dynamics. Loss of CD98hc
reduces sphingolipid availability, leading to defects in movement,
recruitment and activation of regulatory proteins upstream of
RhoA (Figure 2A). Therefore, it is suggested that there is a cross-
talk between sensing the mechanical forces that cells are exposed
to and their metabolic state. This suggests that cancer cells could
benefit from different environmental mechanical forces through
metabolic adaptation. Indeed, it has been demonstrated that
circulating tumor cells display an oxidative switch, while the cells
in the primary tumor are mostly glycolytic (35). An intriguing
explanation for this phenotype could be the loss of mechanical
forces present in the primary tumor. Further studies are needed
to address this point, as invasive cancer cells experience different
mechanical forces during their migration (36).
STRATEGIES UNDERTAKEN BY CANCER
CELLS TO SCAVENGE NUTRIENTS FROM
THE MICROENVIRONMENT
Even though blood pressure inside the tumors is low due
to high interstitial pressure, lymphatic deficiency and leaky
blood vessels increase the accessibility of cancer cells to the
blood serum or its main protein, albumin (37, 38). Ras-
driven cancer cells have a higher rate of macropinocytosis
which helps them to internalize extracellular proteins (ECPs).
In Ras-driven pancreatic ductal adenocarcinoma cells (PDACs)
and Ras-transformed MEFs, amino acid starvation induces
albumin macropinocytosis followed by lysosomal degradation
and amino acid extraction (Figure 2B). It has also been
revealed that mimicking nutrient starvation by inhibiting
mTORC1 signaling pathway induces cells to rely on extracellular
macromolecules rather than amino acids (19, 39, 40). Lack
of nutrient and oxygen delivery leads to cell death at the
center of tumors. In PTEN-deficient prostate cancer cell lines
and KRas-driven pancreatic cancer cells, AMPK activation and
mTORC1 suppression under amino acid and glucose starvation
assist cell proliferation through inducing cell debris scavenging.
It was revealed that amino acids extracted from cell debris
can participate in building cell biomass (41). In addition to
the access to albumin and cell debris, PDAC cells are also
surrounded by a dense network of ECM containing collagen I
and collagen IV. PDAC cells are able to internalize collagen I
and IV through macropinocytosis under glucose starvation and
receptor-dependent endocytosis under low glutamine conditions
(Figure 2B). PDAC cells degrade the internalized collagens in
the lysosomes, providing a source of proline. Proline is then
fed into the TCA cycle, leading to ATP production and cell
survival, via the activation of the ERK1/2 pathway. Contrary
to albumin, collagen uptake in this context does not affect
mTORC1 signaling pathway, and the role of mTOR inhibition
has not been addressed (42). It is not clear whether other
amino acids from the collagen also contribute to cancer cell
survival. Even though the role of Ras has been highlighted in
terms of inducing macropinocytosis under starvation conditions,
its role could be dispensable in the presence of growth
factors. Indeed, it has been demonstrated that MEFs are
be able to induce ECP uptake through growth-factor (GF)
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dependent macropinocytosis, in a PI3 kinase-dependent manner
(Figure 2B). Under amino acid starvation, activation of Rac1 and
PLCγ as an PI3K effector induces ECP macropinocytosis, while
availability of glucose and amino acids induces AKT-dependent
activation of mTORC1 signaling. This allows cells to use free
amino acid from transporters instead of macropinocytosis to
uptake macromolecules (43). PDAC cells are heterogenous
in terms of macropinocytosis potential. A subset of PDAC
tumors have been shown to upregulate macropinocytosis under
glutamine starvation conditions, while other tumors display
constitutive macropinocytosis which is not affected by the level
of nutrients. Mechanistically, glutamine starvation potentiates
EGFR signaling, leading to the activation of the Ras/Pak signaling
pathway. This in turn induces ECP macropinocytosis, followed
by lysosomal degradation (44). Along with in vitro studies
showing that cancer cells can use albumin as an alternative
source of nutrients, hypoalbuminemia was also seen in some
cancer patients (45). An in vivo study directly showed that
PDAC cells inside the tumor are able to internalize albumin
through macropinocytosis and use albumin derived amino
acids for further metabolic pathways, while adjacent normal
cells do not have this ability (46). In addition to taking
advantage of unusual protein sources, cancer cells are able
to use extracellular lipids for their survival under hypoxia or
starvation conditions. Cancer cells need lipid and fatty acids to
reproduce their membrane and proliferate. In normal oxygen
conditions (normoxia), cancer cells can produce non-essential
fatty acids. In contrast, hypoxic or Ras- driven cancer cells
rely on scavenging fatty acids from TME. Ras-driven cancer
cells can internalize serum lipids with one fatty acid tail
(lysophospholipid) to compensate the lack of lipid production
(47). Under glucose and amino acid starvation lipid droplet
(LP) content of cancer cells declines. PTEN-deficient prostate
cancer cells rely on lipids extracted from cell debris through
macropinocytosis to replenish their LP storage containing fatty
acids and cholesterol (41). Invasive breast cancer cells also
show higher proliferation and migration in co-culture with
obese adipocytes. Transferring of fatty acids from adipocytes
to invasive breast cancer cells induces adipose triglyceride
lipase (ATGL)-mediated lipolysis and oxidation of fatty acids in
mitochondria (48).
Since cancer cells could face different nutrient conditions in
various niches during their development, further work is needed
to elucidate how ECP and ECM could affect nutrient availability
and how Ras and PI3K pathways would interact and affect each
other in response to different nutrient conditions.
CONCLUSIONS AND FUTURE
DIRECTIONS
Cancer cells display an elevated metabolic plasticity, allowing
them to adapt to different environments and nutrient levels.
The TME, in particular CAFs and cell-ECM interaction, are
key in controlling this metabolic switch. CAFs secrete several
metabolites, including lactate, pyruvate and aspartate, which have
been shown to support the growth of different cancer cell types
(3). Moreover, through the generation of a stiffer ECM, CAFs
drive changes in cancer cell metabolism, leading to an increase
in one-carbon metabolism and oxidative glutamine metabolism
in the TCA cycle. Furthermore, ECM components, such as
fibronectin and laminin, have been shown to be internalized in an
integrin-dependentmanner and to control nutrient signaling. On
the other hand, it is now clear that nutrient-dependent signaling
pathways can control integrin trafficking and activation in diverse
ways. However, more work needs to be done to elucidate how
nutrient starvation impinges on vesicular trafficking and receptor
internalization in complex 3D environments.
Elevated rates of tumor growth and limited blood supply
result in a nutrient-deprived TME. These pushes cancer cells
to adopt different strategies to obtain metabolic fuels. These
include the internalization of ECP, ECM and cell debris. Despite
all these processes have been observed, the cross-talk between
different nutrient scavenging strategies and how cells can switch
between them have not been fully addressed yet. Importantly, it
is not known how changes in the TME, including immune cell
infiltration and ECM composition and structure, affect the ability
of cancer cells to grow under nutrient deprived conditions.
Altogether, understanding how cancer cells can thrive
within the challenging TME will lead to the identification
of cancer vulnerabilities. These could then be exploited
for the development of novel strategies for targeting
unresponsive tumors.
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